Light gray square, with a dark gray border on the sides.

Blog

One Cardiac Platform. Triple the Impact

February 24, 2026

Why a Unified Cardiovascular Imaging Platform Wins


A single cardiovascular imaging post-processing platform like Circle’s cvi42 turns fragmented workflows into a unified, scalable engine for clinical, technical, and operational performance while reducing the hidden risks of a “best-of-breed” tool stack. 


Why a single platform beats best-of-breed 


The best-of-breed approach sounds appealing: you pick the “perfect” tool for every modality. However, it creates friction at every layer. Complex integrations, security management, and user experience gaps between multiple vendors erode efficiency. A single cardiovascular platform consolidates these functions, so you optimize once and benefit everywhere.

cvi42 single platform for cardiac imaging in healthcare enterprise

Technical and operational gains 


For IT and operations teams, a unified platform delivers: 


  • One architecture to secure and monitor: unified authentication, standardized hardening, and fewer exposed endpoints. 
  • Simplified integrations: one connection for PACS/VNA, EMR, DICOM, HL7, and Reporting interfaces. 
  • Predictable performance: tested deployment patterns and stable turnaround times across MR and CT. 
  • Streamlined support: one vendor, one ticketing path, and fewer “finger-pointing” cycles. 


For users and department leaders, benefits include: 


  • consistent workspace across MR, CT, structural heart, and EP. 
  • Shared AI-driven tools that behave the same way for any case. 
  • Standardized protocols and reports supporting collaboration and guideline adherence. 

This consistency reduces variation, simplifies cross-coverage, and creates clearer levers to improve throughput and quality. 


The effort and risk of going single platform 


Consolidating onto one platform isn’t “zero effort.” Migration, data mapping, and user training take planning. Decision makers often worry about vendor dependence or shortterm disruption. 


Yet these are finite risks while the costs of staying fragmented compound every year. Leaders often overestimate the pain of change and underestimate the ongoing “tax” of complexity. A phased rollout, superuser model, and structured training plan turn risk into a manageable project, while the status quo continues to erode capacity and margins. 


Why wait? 


Every month with multiple systems is a month lost to inefficiency: repeated data entry, switching tools, and unused automation. These slow the adoption of reimbursable capabilities like AI-enabled coronary plaque analysis and add invisible burnout risks for your staff. 

 

Stay tuned for Part 2: Clinical and Financial Wins that Scale. Now that we’ve explored the technical and operational foundations of a unified platform, we’ll shift our focus to the bigger picture of strategic advantage. We’ll discuss how consolidation creates tangible impact for everyone from clinicians to executives—exploring volume-aligned pricing and the opening window for new reimbursable procedures like AI-enabled coronary plaque analysis. 

Triple threat: illustrations showing anatomical heart, heart with clock, and inflamed heart with viruses.
March 12, 2026
The Clinical Challenge & the cvi42 Solution Executive Summary Cardiovascular disease remains the leading cause of global mortality, yet diagnostic workflows remain fragmented. Traditionally, clinicians have been forced to navigate disconnected systems to assess a patient’s heart: one for anatomy (CCTA), another for function (CMR/Strain), and a third for vascular inflammation (PCAT/Plaque). This "siloed" approach creates diagnostic friction, increases costs, and delays life-saving interventions.
March 10, 2026
Clinical and Financial Wins that Scale From Single Platform to Strategic Advantage Clinicians, department heads, and executives each win differently from consolidation. Circle’s cvi 42 turns integration into tangible impact across MR, CT, structural heart, and electrophysiology programs. Why Circle’s platform stands apart For clinicians: Market-leading MR and CT tools in one workspace, with AI-driven workflows for function, tissue, plaque, and procedural planning—faster, reproducible reads and intuitive tools for edge cases. For department heads: Consistent multimodality workflows, research-grade quantification, and data exports supporting registries and AI projects. For finance leaders: Shared investment across MR and CT service lines, volumealigned pricing, and new reimbursable procedures like AIenabled coronary plaque analysis. 
March 5, 2026
The activation of Category I CPT code 75577 on January 1, 2026, has transformed the reimbursement landscape for AI-enabled coronary plaque analysis, such as Circle Cardiovascular Imaging's FDA-cleared cvi 42 . This FAQ addresses key questions on payers, coverage, coding, payments, opportunities, threats, and value-based care impacts to guide adoption in cardiovascular imaging practices that ultimately lead to commercial viability. For Circle Cardiovascular Imaging customers deploying cvi 42 for plaque analysis, the new CPT 75577 landscape means reliable revenue streams (~$900-1,000 per case) with expanded payer access, but it requires refined billing to navigate bundling and denials. Overall, it accelerates the ROI on cvi 42 by enabling onsite AI processing that captures professional and technical fees hospitals previously outsourced.
October 15, 2025
Decoding the Coronaries CAD-RADS, or the Coronary Artery Disease Reporting and Data System, is a standardized reporting system designed to enhance the communication of coronary artery disease (CAD) findings from imaging studies. CAD-RADS represents a significant step towards a more systematic and evidence-based approach to the management of CAD. By standardizing reporting, guiding clinical decisions, facilitating research, and improving risk stratification, CAD-RADS not only holds the potential to improve the clarity of communication between the diagnostician and the downstream physician, but at a larger scale, it could contribute significantly to better cardiovascular health outcomes across populations. 

Subscribe to our newsletter

 Don’t miss future articles or publications.